Abstract 501P
Background
For locally advanced unresectable NSCLC, studies of PD-1 inhibitor plus chemo as induction therapy and its roles in subsequent surgical resection are still limited. In this study, a consecutive series of unresectable stage III NSCLC patients were collected to investigate the surgical outcome and survival outcomes in locally advanced patients who received preoperative chemotherapy combined with immunotherapy.
Methods
92 locally advanced NSCLC patients received 2-4 cycles of chemotherapy combined with immunotherapy. Surgical rates, major pathologic remissions(MPR), pathologic complete remissions(PCR), postoperative complications, and immune-related adverse reactions(irAEs) were assessed. Disease-free survival(DFS) and overall survival(OS) were analyzed in 45 patients who were followed up at least one year after the surgery.
Results
71.74% of patients underwent surgical resection. 63.64% (42/66) achieved MPR and PCR, of which 37.87% (25/66) were PCR. 26.09% of patients developed irAEs, the most common was skin toxicity, followed by thyroid dysfunction. Of the 47 patients who received the surgery more than one year, only 4.3%(2/47) of patients lost the followed-up. 8 patients suffered from recurrence and 4 were died of the disease. One year disease-free survival rate was 88.9%(40/45) and one year over-all survival rate was 97.8%(44/45).
Conclusions
Preoperative chemotherapy combined with immunotherapy provides more opportunities for radical resection and acceptable survival outcomes in unresectable locally advanced NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xin Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract